Skip to content
Open access

Dysregulated KMT2D mutant targeting immunogenic rewiring to overcome epigenetic entropy promotes follicular lymphomagenesis

Sep 2026 · Experimental Hematology & Oncology · Vol 15 · 0 citations · 51 references
Medicine

TL;DR

A central molecular network through which KMT2Dmut operates in follicular lymphoma subsets is delineated and provided a mechanistic rationale for therapeutic targeting of KMT2D.

Abstract

Epigenetic modifier factors in B cell lymphomas often harbor loss-of-function mutations. Mutations occurring in the histone-lysine methyltransferase 2D (KMT2D) gene are the pivotal chromatin-modifying hallmarks of follicular lymphoma (FL) subsets, however their tumor-promoting roles are unclear. Targeted sequencing was employed to evaluate a core panel of genes implicated in histone methylation (EZH2, KMT2D), histone acetylation (CREBBP, EP300), and chromatin remodeling (ARID1A, BCL7A) in FL patients. Functional characterization of the KMT2D mutation (KMT2Dmut) was carried out in vitro. RNA sequencing analysis was utilized to identify differentially expressed genes (DEGs) and significantly enriched pathways. The role of aldehyde dehydrogenase 1 family member A1 (ALDH1A1) in mediating the function of the KMT2Dmut was investigated in B-lymphoma cell models using lentivirus. Through transcriptome deconvolution, integrative analyses combining chromatin immunoprecipitation and genome-wide chromatin accessibility were performed in KMT2D-mutant cell lines. Additionally, chromatin immunoprecipitation, immunofluorescence assays, and immunoblotting analyses were conducted. KMT2D mutations were the most frequent genetic alterations in FL (63%), predominantly consisting of nonsense and frameshift variants. Compared with wild-type, KMT2D-mutant FL exhibited markedly reduced H3K9me3 levels and increased chromatin accessibility at distal regulatory regions. Functionally, KMT2Dmut promoted proliferation, suppressed apoptosis, and arrested cells in G2 phase. In FL, mutant KMT2D suppressed H3K9 methylation, leading to ALDH1A1 upregulation and the emergence of a highly plastic B‑cell state, followed by ATP7A overexpression, which ultimately reshaped the immune microenvironment. KMT2Dmut drives FL progression by relieving H3K9me3-mediated epigenetic modification, activating PDK1/SGK1 signaling and an ALDH1A1-driven stemness program, and upregulating ATP7A to rewire copper homeostasis and redox balance. Our findings delineate a central molecular network through which KMT2Dmut operates in FL and provide a mechanistic rationale for therapeutic targeting of KMT2D.

Read PDF

Similar papers

Review Open access Aug 2026

Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy

Epigenetic dysregulation is a hallmark of glioblastoma (GBM) pathogenesis, with histone methylation playing a central role in chromatin remodeling and gene expression regulation. Enhancer of zeste homolog 2 (EZH2) is a key epigenetic regulator responsible for histone methylation. It primarily functions as a transcripti...

J. Grzegorzewski, M. Lindner, Dagmara Lisińska et al. · 0 citations
Open access Aug 2026

Targeting SUV4–20H2-mediated H4K20 methylation restrains growth and migration in pediatric high-grade astrocytomas

Pediatric astrocytomas are characterized by increased molecular and clinical heterogeneity with epigenetic alterations contributing to aggressiveness and therapy resistance. The repressive histone mark H4K20 trimethylation (H4K20me3) and the methyltransferase SUV4–20H2 (KMT5C) are critical regulators of chromatin integ...

A. Giannopoulou, Elisavet Kosma, Dimitrios S. Kanakoglou et al. · 0 citations
Open access Sep 2026

Clonal hematopoiesis-associated DNMT3A mutations derepress bivalent Polycomb target genes and enhance macrophage migration

Somatic mutations in the de novo DNA methyltransferase DNMT3A are frequent in clonal hematopoiesis, but how they alter the function of differentiated myeloid cells remains unclear. Here, we used isogenic human embryonic stem cell-derived macrophage models to define the consequences of DNMT3A dysfunction during myeloid...

Yuri Lee, Philip K. Farahat, J. Nguyen et al. · 0 citations
#gene editing Open access Sep 2026

Mutant ASXL1 Cooperates with MECOM and BRD4 to Drive Transcriptional Dysregulation in Human Hematopoiesis.

Mutations in the epigenetic regulator ASXL1 are common in myeloid malignancies and portend a near-universally poor prognosis. While multiple mechanisms for mutant ASXL1-dependent oncogenesis have been proposed, none have been functionally validated in the context of the human hematopoietic stem cell, where these mutati...

Madison L. Hall, Aliya Quintal, Sonia N. Acharya et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.